Prognosis

Annovis Announces Unblinding of the Buntanetap Phase III Data in Parkinson’s Disease

Retrieved on: 
Thursday, May 9, 2024

MALVERN, Pa., May 09, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, today announced successful completion of data cleaning for its Phase III study of buntanetap in patients with early Parkinson’s disease (PD).

Key Points: 
  • MALVERN, Pa., May 09, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, today announced successful completion of data cleaning for its Phase III study of buntanetap in patients with early Parkinson’s disease (PD).
  • The Phase III study was completed in 4Q 2023 with an original plan for data announcement in 1Q 2024, however the Company faced a delay in the process of data cleaning beyond the original prognosis.
  • Maria Maccecchini, Ph.D., Founder, President, and CEO of Annovis, explains in detail the reason behind this delay:
    "When we reached the point of unblinding the data for the PD Phase III study, we discovered an unexpected issue: too many plasma samples showed no presence of buntanetap.
  • We were expecting 33% blank samples from the placebo group, but we saw over 50% blank samples.

Akoya Biosciences and NeraCare Enter into an Exclusive Agreement to Enable Personalized Therapy Selection for Early-Stage Melanoma Patients

Retrieved on: 
Thursday, May 9, 2024

Melanoma is the leading cause of skin cancer-related deaths, with over 235,000 new diagnoses globally every year.

Key Points: 
  • Melanoma is the leading cause of skin cancer-related deaths, with over 235,000 new diagnoses globally every year.
  • Recent approvals of immune- and targeted therapies have greatly expanded the available treatment options for adjuvant therapy.
  • Nonetheless, a significant number of early-stage melanoma patients remain at high risk of relapse and mortality without access to such therapies.
  • As the majority of melanoma patients are diagnosed with early stage disease, there is a critical unmet medical need to identify those at-risk patients to potentially enable earlier access to life-saving therapeutic agents.

Bionano Reports First Quarter 2024 Results and Highlights Recent Business Progress

Retrieved on: 
Wednesday, May 8, 2024

Reiterated full year 2024 revenue guidance of $37.0 to $41.0 million; revenue for the second quarter of 2024 is expected to be $7.8 to $8.2 million.

Key Points: 
  • Reiterated full year 2024 revenue guidance of $37.0 to $41.0 million; revenue for the second quarter of 2024 is expected to be $7.8 to $8.2 million.
  • GAAP gross margin for the first quarter of 2024 was 32%, compared to 28% from the first quarter of 2023.
  • First quarter 2024 non-GAAP gross margin was 34%, compared to 30% from the first quarter of 2023.
  • Gülsen Kama, chief financial officer at Bionano added, “Q1 2024 was an important quarter for the Company.

Global Nebulizers Research Report 2024: Market to Reach $2.5 Billion by 2032 - Product Type, Portability, End-User, Application Analysis - ResearchAndMarkets.com

Retrieved on: 
Thursday, May 9, 2024

The "Global Nebulizers Market Report by Product Type, Portability, End-User, Application, and Region 2024-2032" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Nebulizers Market Report by Product Type, Portability, End-User, Application, and Region 2024-2032" report has been added to ResearchAndMarkets.com's offering.
  • The global nebulizers market is witnessing an impressive growth trajectory, with projections indicating a market value of US$ 2.5 Billion by the year 2032.
  • The global nebulizers market report meticulously segments the market by product type, portability, end-user, and application, presenting an in-depth analysis of each sector and its projected growth.
  • The global nebulizers market is on a steady growth path and encapsulates significant opportunities across varied sectors.

Autoimmune Disease Diagnostics Market Research, Size, Global Forecasts 2024-2030: Robotics and AI, Autoantibody Assays and Genetic Testing, & Innovative Biomarkers Drive Expansion - ResearchAndMarkets.com

Retrieved on: 
Thursday, May 9, 2024

The growing old global population, specifically susceptible to autoimmune illnesses, fuels a growing diagnostics market.

Key Points: 
  • The growing old global population, specifically susceptible to autoimmune illnesses, fuels a growing diagnostics market.
  • By product, the global autoimmune diseases diagnostics market is fragmented into Therapeutic & Monitoring Equipment, Diagnostics Equipment, and Drugs.
  • The global autoimmune diseases diagnostics market is segmented into Systemic Autoimmune Disease Diagnostics and Localized Autoimmune Disease Diagnostics.
  • By indication, the global autoimmune diseases diagnostics market is categorized into Rheumatic Disease, Diabetes, Multiple Sclerosis, Inflammatory Bowel Disease, and Others.

Bionic Devices Market, Size, Global Forecast 2024-2030: Demand Grows for Rehabilitation and Functional Recovery Solutions - ResearchAndMarkets.com

Retrieved on: 
Thursday, May 9, 2024

The demand for bionic devices has surged in modern times because of their transformative effect on the quality of existence.

Key Points: 
  • The demand for bionic devices has surged in modern times because of their transformative effect on the quality of existence.
  • Technological improvements and extensive research and improvement efforts are critical drivers for expanding the development of the global bionic devices market.
  • This developing emphasis on rehabilitation and functional healing is vital to adopting and utilizing bionic devices.
  • These establishments function as hubs for prognosis, treatment, and rehabilitation, propelling the demand for bionic devices throughout numerous scientific specialties.

BostonGene and the Medical College of Wisconsin Announce the Publication and Journal Cover Feature in Gastroenterology Highlighting Transcriptomic-Based Tumor Microenvironment Classification for Precision Medicine in Pancreatic Cancer

Retrieved on: 
Monday, May 6, 2024

BostonGene’s artwork was also chosen for the cover of the May publication.

Key Points: 
  • BostonGene’s artwork was also chosen for the cover of the May publication.
  • The journal highlights original research, reviews and expert insights in adult and pediatric gastroenterology and hepatology, covering clinical, translational and basic aspects of the digestive system, liver, pancreas and nutrition.
  • The study identified four distinct tumor microenvironment (TME) subtypes, unveiling a promising path forward in the fight against PDAC and underscoring the importance of considering TME features in personalized therapeutic strategies.
  • “For a long while, the scientific community believed that pancreatic cancer was not responsive to immunotherapy, which uses a person’s own immune system to fight cancer.

Newly Published Data in JAMA Cardiology Demonstrates Favorable Long-term Effects of the Corvia Atrial Shunt in Heart Failure Patients

Retrieved on: 
Tuesday, May 7, 2024

TEWKSBURY, Mass., May 7, 2024 /PRNewswire/ -- Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure, today announced the publication in JAMA Cardiology of two-year echocardiographic data from its REDUCE LAP-HF II randomized clinical trial of the Corvia® Atrial Shunt, offering groundbreaking insight into the impact of a shunt on the heart.

Key Points: 
  • TEWKSBURY, Mass., May 7, 2024 /PRNewswire/ -- Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure, today announced the publication in JAMA Cardiology of two-year echocardiographic data from its REDUCE LAP-HF II randomized clinical trial of the Corvia® Atrial Shunt, offering groundbreaking insight into the impact of a shunt on the heart.
  • The study demonstrated favorable long-term effects of atrial shunting on heart structure and function in patients with heart failure with preserved or mildly reduced ejection fraction (HFpEF/HFmrEF).
  • Analysis showed that atrial shunting led to favorable cardiac remodeling, restoration of the heart's normal function, with resulting improvements in clinical outcome and prognosis.
  • "The findings of our study support the referral of suitable patients to RESPONDER-HF, a randomized, sham-controlled trial now underway in the US, Europe and Australia in pursuit of the evidence required to achieve FDA approval of the Corvia Atrial Shunt for millions of heart failure patients."

Wistar Scientists Discover New Immunosuppressive Mechanism in Brain Cancer

Retrieved on: 
Friday, May 3, 2024

The lab’s discovery was published in the paper, “ Glucose-driven histone lactylation promotes the immunosuppressive activity of monocyte-derived macrophages in glioblastoma ,” in the journal Immunity.

Key Points: 
  • The lab’s discovery was published in the paper, “ Glucose-driven histone lactylation promotes the immunosuppressive activity of monocyte-derived macrophages in glioblastoma ,” in the journal Immunity.
  • Indeed, monocyte-derived macrophages, but not microglia, blocked the activity of T cells (immune cells that destroy tumor cells), in preclinical models and patients.
  • Glioblastoma is inherently dangerous due to its location in the brain and its immunosuppressive tumor microenvironment, which renders glioblastoma resistant to promising immunotherapies.
  • Note: The work detailed in this publication was initiated at The H. Lee Moffitt Cancer Center during Dr. Veglia’s time there and continued at Wistar.

MiRNA Sequencing and Assay Market Research 2024: Robust Growth with Emerging Trends in Personalized Medicine and Advancements in Sequencing Technologies - Global Forecasts to 2029 - ResearchAndMarkets.com

Retrieved on: 
Friday, May 3, 2024

One of the primary drivers of the global miRNA sequencing and assay market is the rising demand for personalized medicine and precision diagnostics.

Key Points: 
  • One of the primary drivers of the global miRNA sequencing and assay market is the rising demand for personalized medicine and precision diagnostics.
  • This has led to a surge in the adoption of miRNA sequencing and assay technologies in both research and clinical settings.
  • The integration of bioinformatics tools has emerged as a significant driver in boosting the Global MiRNA Sequencing and Assay Market.
  • The rising interest in personalized medicine has emerged as a powerful catalyst in boosting the Global MiRNA Sequencing and Assay Market.